• LAST PRICE
    11.3500
  • TODAY'S CHANGE (%)
    Trending Down-1.5300 (-11.8789%)
  • Bid / Lots
    11.1000/ 1
  • Ask / Lots
    11.3500/ 5
  • Open / Previous Close
    12.8700 / 12.8800
  • Day Range
    Low 10.9100
    High 13.5500
  • 52 Week Range
    Low 4.3200
    High 22.5000
  • Volume
    411,388
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 12.88
TimeVolumeIGMS
09:32 ET314812.87
09:37 ET60412.915
09:39 ET110313.0362
09:42 ET230513.05
09:46 ET22513.55
09:51 ET327812.955
09:53 ET21612.8331
09:55 ET171413.3859
10:06 ET135712.77
10:09 ET47012.5301
10:13 ET20012.655
10:20 ET129112.45
10:22 ET13012.31
10:27 ET10012.36
10:29 ET191312.35
10:31 ET12012.31
10:42 ET40012.35
10:47 ET90012.28
10:51 ET10012.425
10:56 ET110012.12
10:58 ET56412.3212
11:00 ET151312.14
11:02 ET10012.353
11:05 ET52512.14
11:20 ET20012.275
11:21 ET10012.295
11:25 ET70012.14
11:27 ET10012.12
11:36 ET10012.13
11:38 ET304411.97
11:39 ET90511.86
11:41 ET150011.935
11:43 ET70011.81
11:45 ET186311.85
11:48 ET23211.82
11:50 ET441711.77
11:56 ET332611.86
12:06 ET20011.77
12:08 ET50011.825
12:10 ET141511.825
12:14 ET152911.825
12:15 ET201811.74
12:17 ET64111.64
12:19 ET354311.795
12:21 ET30011.74
12:24 ET20011.755
12:26 ET20011.755
12:28 ET20011.755
12:30 ET10011.755
12:32 ET10411.7506
12:35 ET150011.715
12:37 ET542011.71
12:39 ET345311.67
12:42 ET254111.6
12:44 ET350011.65
12:46 ET100011.62
12:50 ET10011.6
12:51 ET39911.59
12:53 ET30011.57
12:55 ET38611.54
12:57 ET76611.593
01:00 ET180011.465
01:02 ET444411.4975
01:04 ET150011.53
01:08 ET30011.525
01:09 ET55011.525
01:11 ET100011.55
01:15 ET50011.53
01:18 ET241311.69
01:20 ET258711.56
01:31 ET10011.505
01:33 ET387711.51
01:38 ET27011.52
01:40 ET20011.47
01:44 ET43911.42
01:47 ET206311.4
01:49 ET10011.39
01:51 ET469811.37
01:54 ET345011.4
01:56 ET63411.4
02:03 ET161211.41
02:05 ET10011.41
02:12 ET120011.48
02:16 ET181911.37
02:20 ET50011.36
02:25 ET132711.3201
02:27 ET706911.25
02:30 ET10011.265
02:32 ET132011.29
02:34 ET110011.27
02:36 ET309511.37
02:38 ET60211.4
02:43 ET270411.39
02:45 ET179911.395
02:50 ET30011.35
02:52 ET10011.35
02:56 ET50011.2901
02:57 ET801611.17
02:59 ET90011.17
03:01 ET30011.17
03:03 ET70811.21
03:06 ET60011.26
03:08 ET100011.25
03:10 ET180011.2
03:12 ET219911.2525
03:14 ET50011.23
03:15 ET40011.27
03:17 ET348911.3
03:19 ET25011.3121
03:21 ET10011.265
03:24 ET3829211.015
03:26 ET250411.035
03:28 ET316110.94
03:30 ET319510.92
03:32 ET20010.93
03:33 ET370010.95
03:35 ET144010.95
03:37 ET100010.95
03:42 ET2001411.045
03:44 ET140011.11
03:46 ET174011.145
03:48 ET86911.13
03:50 ET30011.15
03:51 ET200011.18
03:53 ET136511.145
03:55 ET411611.125
03:57 ET3230711.105
04:00 ET5733011.35
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesIGMS
IGM Biosciences Inc
764.0M
-3.1x
---
United StatesOCS
Oculis Holding AG
667.5M
-7.4x
---
United StatesCATX
Perspective Therapeutics Inc
747.8M
-7.7x
---
United StatesBIOA
BIOAGE Labs Inc
774.6M
-11.0x
---
United StatesAVXL
Anavex Life Sciences Corp
775.9M
-18.0x
---
United StatesMBX
MBX Biosciences Inc
785.3M
-15.3x
---
As of 2024-11-12

Company Information

IGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. IGM-2644 is a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins.

Contact Information

Headquarters
325 E Middlefield RdMOUNTAIN VIEW, CA, United States 94043-4003
Phone
650-965-7873
Fax
302-655-5049

Executives

Chief Executive Officer, Director
Mary Harler
Chief Financial Officer
Misbah Tahir
Chief Business Officer
Lisa Decker
Independent Director
Felix Baker
Independent Director
M. Kathleen Behrens

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$764.0M
Revenue (TTM)
$2.9M
Shares Outstanding
59.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.13
EPS
$-3.65
Book Value
$3.46
P/E Ratio
-3.1x
Price/Sales (TTM)
261.8
Price/Cash Flow (TTM)
---
Operating Margin
-8,043.83%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.